Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates include IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia. The company also develops compounds, such as AMG 172 that is in Phase I clinical trials for the treatment of clear cell renal cell carcinoma; AMG 595, which is in Phase I clinical trials for treating glioblastoma; BAY 94-9343 is in early clinical trials for the t
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||98.97%||Sales Growth - Q/Q||-76.34%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-42.42%||ROE||-95.13%||ROI|
|Current Ratio||5.22||Quick Ratio||5.1||Long Term Debt/Equity||Debt Ratio||0.38|
|Gross Margin||Operating Margin||-71.01%||Net Profit Margin||-72.15%||Dividend Payout Ratio|
|Cash From Financing Activities||1.43 M||Cash From Investing Activities||-5.03 M||Cash From Operating Activities||-26.84 M||Gross Profit|
|Net Profit||-30.47 M||Operating Profit||-25.09 M||Total Assets||313.82 M||Total Current Assets||278.11 M|
|Total Current Liabilities||35.81 M||Total Debt||Total Liabilities||278.72 M||Total Revenue||12.61 M|
|High 52 week||12.95||Low 52 week||3.94||Last close||5.46||Last change||-1.8%|
|RSI||57.53||Average true range||0.42||Beta||1.44||Volume||965.36 K|
|Simple moving average 20 days||11.98%||Simple moving average 50 days||2.37%||Simple moving average 200 days||-37.2%|
|Performance Week||14.23%||Performance Month||2.25%||Performance Quart||-33.5%||Performance Half||-50.54%|
|Performance Year||-18.51%||Performance Year-to-date||13.75%||Volatility daily||5.09%||Volatility weekly||11.37%|
|Volatility monthly||23.31%||Volatility yearly||80.74%||Relative Volume||259.72%||Average Volume||2.72 M|
|New High||New Low|
2019-01-18 15:00:19 | Have Insiders Been Selling ImmunoGen, Inc. NASDAQ:IMGN Shares This Year?
2019-01-08 16:01:00 | ImmunoGen Announces Sale of Residual Kadcyla Royalties
2019-01-07 17:20:00 | Why ImmunoGen Jumped Today
2018-12-26 16:18:00 | Why ImmunoGen Shot Up 13% Today
2018-12-17 21:52:44 | Hedge Funds Are Betting On ImmunoGen, Inc. IMGN
2018-12-06 14:49:07 | Roche's Kadcyla Halves Death Risk in Breast Cancer Study
2018-12-02 09:30:02 | ImmunoGen IMGN Down 7.2% Since Last Earnings Report: Can It Rebound?
2018-11-26 16:47:15 | Former Aveo exec resigns as ImmunoGen CFO after fraud verdict
2018-11-26 16:01:00 | ImmunoGen Announces Resignation of Chief Financial Officer
2018-11-25 09:41:17 | The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings
2018-11-21 11:23:32 | Former Aveo CFO misled biotech's investors, jury finds
2018-11-20 08:31:01 | Are Options Traders Betting on a Big Move in ImmunoGen IMGN Stock?
2018-11-14 11:35:00 | Healthcare Stocks with Turnaround Potential
2018-11-12 07:32:00 | How Has Cara Therapeutics’ 2018 Performance Shaken Out?
2018-11-09 14:12:00 | ImmunoGen Waits to Leap "Forward"
2018-11-07 20:28:22 | Here's Why ImmunoGen Closed Almost 12% Up on Wednesday
2018-11-07 09:46:29 | Here's Why ImmunoGen Shares Lost 42.7% in October
2018-11-06 16:30:00 | ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
2018-11-05 11:01:53 | How ImmunoGen Inc NASDAQ:IMGN Can Impact Your Portfolio Volatility
2018-11-05 09:35:02 | ImmunoGen IMGN Beats on Earnings in Q3, Lowers Guidance
2018-11-02 12:25:46 | Edited Transcript of IMGN earnings conference call or presentation 2-Nov-18 12:00pm GMT
2018-11-02 12:12:15 | Immunogen Inc IMGN Q3 2018 Earnings Conference Call Transcript
2018-11-02 10:43:46 | MARKETS: Today's job numbers might have been too good and could spook stocks
2018-11-02 09:40:01 | ImmunoGen IMGN Reports Q3 Loss, Lags Revenue Estimates
2018-11-02 08:36:35 | ImmunoGen: 3Q Earnings Snapshot
2018-11-02 06:30:00 | ImmunoGen Reports Recent Progress and Third Quarter 2018 Operating Results
2018-11-01 14:55:52 | Q3 Earnings Outlook For ImmunoGen
2018-10-26 10:30:02 | ImmunoGen IMGN Q3 Earnings Preview: What to Look Out For
2018-10-22 11:05:00 | Here's Why ImmunoGen Fell Today
2018-10-18 16:30:00 | ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2018 Operating Results
2018-10-15 10:30:00 | Cancer Companies to Watch
2018-10-14 13:21:15 | The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs
2018-10-10 08:30:00 | Report: Developing Opportunities within Southwest Airlines, Select Income REIT, Oxford Industries, ImmunoGen, Navigant Consulting, and TrueBlue — Future Expectations, Projections Moving into 2018
2018-10-08 09:50:01 | Are Options Traders Betting on a Big Move in ImmunoGen IMGN Stock?
2018-10-05 17:00:00 | Why ImmunoGen Inc. Dropped 8% Today
2018-10-04 17:53:17 | Why ImmunoGen, Inc. Fell 10.6% on Thursday
2018-09-24 16:30:00 | ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
2018-09-19 08:31:37 | Who Owns Most Of ImmunoGen Inc NASDAQ:IMGN?
2018-08-27 16:30:00 | ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
2018-08-06 07:45:00 | Investor Expectations to Drive Momentum within Ingevity, First Industrial Realty Trust, ImmunoGen, PriceSmart, Pacific Gas & Electric, and Procter & Gamble — Discovering Underlying Factors of Influence